HomeTagsPharmaceutical

pharmaceutical

SGX-LISTED COMPANIES

Camsing Healthcare Faces Severe Going Concern Risks As Q2 FY2027 Deficit Deepens

Camsing Healthcare Survival Strategy and the Massive Share Dilution Investors Need to Understand Camsing Healthcare...
AI

Standard Chartered targets AI scale across 50+ markets to smoothen banking friction

Standard Chartered is prioritising client-focused artificial intelligence initiatives that can be scaled across its...
spot_img
Pharmaceutical

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...
Pharmaceutical

AstraZeneca deploys AI to cut drug timelines by 30% and boost survival

AstraZeneca is stepping up its investment in AI drug discovery to shorten treatment timelines...
SGX-LISTED COMPANIES

The Reason The US Department Of War Awarded iX Biopharma A $41M Contract For A Painkiller

Beyond the Needle and the Pill The opioid epidemic remains one of the most significant...
SGX-LISTED COMPANIES

How Vietnam Is Negatively Impacting Hyphens Pharma’s Growth

The Southeast Asian Pharmaceutical Puzzle Navigating the healthcare landscape in Southeast Asia is often described...
SGX-LISTED COMPANIES

Tianjin Pharmaceutical Da Ren Tang Is Shrinking To Succeed In FY2025

How TJ DRT’s 33% Revenue "Loss" Fueled a 72% Margin Miracle and a Record...
SGX-LISTED COMPANIES

Why China Medical Systems FY2025 Profits Dropped Despite Growth

https://open.spotify.com/episode/3YAldvdzS4eXE4RzkN9M18?si=8a54594510534cfe 5 Game-Changing Takeaways from CMS’s 2025 Transformation For the Chinese pharmaceutical sector, 2025 was the...
SGX-LISTED COMPANIES

iX Biopharma’s Secret Shortcut To The US Medical Market – 1H FY2026

From Cash Burn to Bioavailability: How iX Biopharma Slashed Losses by 67% via a...
SGX-LISTED COMPANIES

Why This Tiny Lab Is Outpacing Global Giants

The $1.5 Trillion Green Transition’s Secret Weapon In the high-stakes theater of the modern economy,...
SGX-LISTED COMPANIES

The Secret To Lonza’s Massive FY2025 Growth

5 Key Takeaways from Lonza's Blockbuster 2025 Report Takeaway 1: Record-Breaking Growth That Beat Expectations The...
SGX-LISTED COMPANIES

One Asset Deal Changed Everything For Tianjin Da Ren Tang In Q3 2025

How Tianjin Da Ren Tang's Revenue Fell 35% While Its Profits Soared: 4 Surprising...
Pharmaceutical

BD tackles shortage in healthcare professionals with robot pharmacy technology

Singapore hospitals are deploying robotic pharmacy technology to ease healthcare workforce shortages, cut patient...
SGX-LISTED COMPANIES

iX Biopharma’s Robust FY2025 Performance and Strategic Outlook

iX Biopharma LTD achieved robust financial performance with significant revenue and gross profit growth,...

Latest articles

SGX-LISTED COMPANIES

Camsing Healthcare Faces Severe Going Concern Risks As Q2 FY2027 Deficit Deepens

Camsing Healthcare Survival Strategy and the Massive Share Dilution Investors Need to Understand Camsing Healthcare...
AI

Standard Chartered targets AI scale across 50+ markets to smoothen banking friction

Standard Chartered is prioritising client-focused artificial intelligence initiatives that can be scaled across its...
SGX-LISTED COMPANIES

All-Link Air & Sea’s 1H FY2026 Revenue Surges But One-Off IPO Costs Hit Bottom Line

All Link Numbers Show Growth Beyond the IPO Noise All-Link Air & Sea Limited has...
SGX-LISTED COMPANIES

Singapore Construction Boom Drives Reclaims Global 1H FY2027

The Strategic Asset Pivot Powering Reclaims Global Massive Growth Streak The Singapore construction sector is...